Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35320359.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0116.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The ADAURA adjuvant randomized trial demonstrated that osimertinib prolonged DFS. It has now been reported that health-related quality of life (HRQoL) was not adversely affected by adjuvant osimertinib. Does this mean that adjuvant osimertinib should now be standard as we await survival results? See related article by Majem et al., p. 2286.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms